

**September 30, 2025**

## PROVIDER ALERT

The MedStar Family Choice Pharmacy and Therapeutics Committee made the decision **to prefer biosimilars for the products listed in table below** in the medical drug formulary **effective November 1, 2025**.

Chemical Name (Drug Class)	HCPCS	Preferred Products	Non-Preferred Products
Aflibercept (VEGF Inhibitor)	Q5147	Pavblu	Eylea
Bevacizumab (VEGF Inhibitor)	Q5118	Zirabev	Avastin Mvasi Vegzelma
Infliximab (TNF inhibitor)	Q5121	Avsola	Remicade Renflexis Inflectra
Pegfilgrastim (Hematopoietic agent)	Q5108	Fulphila	Neulasta Fylmetra Nyvepria Stimufend Udenyca
Ranibizumab (VEGF Inhibitor)	Q5128	Cimerli	Lucentis Byooviz
Rituximab (Anti-CD20 monoclonal antibody)	Q5123 Q5119	Riabni Ruxience	Rituxan Truxima
Tocilizumab (IL-6 antagonist)	Q5135	Tyenne	Actemra Tofidence
Trastuzumab (HER2 receptor antagonist)	Q5114 Q5113	Ogivri Herzuma	Herceptin Kanjinti Ontruzant Trazimera
Denosumab (RANKL inhibitor)	Q5136 Q5157	Jubbonti/Wyost Stoboclo/Osenvelt	Prolia/Xgeva



# MedStar Family Choice

DISTRICT OF COLUMBIA

Chemical Name (Drug Class)	HCPCS	Preferred Products	Non-Preferred Products
Ustekinumab (IL-23 inhibitor)	Q5100 Q5099	Yesintek Stequeyma	Stelara Otulfi Selarsdi Wezlana Pyzchiva

MedStar Family Choice DC will continue to cover any existing non-preferred medical drug services that were already approved prior to November 1, 2025.

If you have any questions, please call 202-363-4348.

Sincerely,

Erica McClaskey, MD, MS, FAAFP  
Chief Medical Officer DC, Senior Medical Director  
MedStar Family Choice DC

**It's how we  
treat people.**